Aclaris therapeutics announces positive results from phase 1 single and multiple ascending dose trial of ati-450

Aclaris therapeutics announces positive results from phase 1 single and multiple ascending dose trial of ati-450, an investigational oral mk2 inhibitor.aclaris therapeutics inc - preliminary data support progression to phase 2a proof of concept trials in immuno-inflammatory diseases.aclaris therapeutics inc - oral small molecule showed marked inhibition of tnfΑ, il1Β, il8, and il6.aclaris therapeutics inc - no serious adverse events or severe adverse events were reported.aclaris therapeutics inc - no adverse events led to discontinuation of study medication.aclaris therapeutics - preliminary data demonstrated ati-450 was generally well-tolerated at all doses tested in trial.aclaris therapeutics - preliminary data demonstrated ati-450 had dose proportional pharmacokinetics with terminal half-life of 9-12 hours.aclaris therapeutics - to initiate first phase 2 clinical trial in subjects with rheumatoid arthritis in 1h 2020.
ACRS Ratings Summary
ACRS Quant Ranking